The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The contribution of MEF2 TFs to the tumorigenic process is still mysterious. Here we clarify that MEF2 can support both pro-oncogenic or tumor suppressive activities depending on the interaction with co-activators or co-repressors partners. Through these interactions MEF2 supervise histone modifications associated with gene activation/repression, such as H3K4 methylation and H3K27 acetylation. Critical switches for the generation of a MEF2 repressive environment are class IIa HDACs. In leiomyosarcomas (LMS), this two-faced trait of MEF2 is relevant for tumor aggressiveness. Class IIa HDACs are overexpressed in 22% of LMS, where high levels of MEF2, HDAC4 and HDAC9 inversely correlate with overall survival. The knock out of HDAC9 suppresses the transformed phenotype of LMS cells, by restoring the transcriptional proficiency of some MEF2-target loci. HDAC9 coordinates also the demethylation of H3K4me3 at the promoters of MEF2-target genes. Moreover, we show that class IIa HDACs do not bind all the regulative elements bound by MEF2. Hence, in a cell MEF2-target genes actively transcribed and strongly repressed can coexist. However, these repressed MEF2-targets are poised in terms of chromatin signature. Overall our results candidate class IIa HDACs and HDAC9 in particular, as druggable targets for a therapeutic intervention in LMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEF2: a central regulator of diverse developmental programs
Potthoff, M. J., & Olson, E. N. (2007) · Development · doi:10.1242/dev.008367 · Cited by 834
Activity-Dependent Regulation of MEF2 Transcription Factors Suppresses Excitatory Synapse Number
Flavell, S. W., Cowan, C. W., Kim, T.-K., Greer, P. L., Lin, Y., Paradis, S., Griffith, E. C., Hu, L. S., Chen, C., & Greenberg, M. E. (2006) · Science · doi:10.1126/science.1122511 · Cited by 573
MEF‐2 function is modified by a novel co‐repressor, MITR
Sparrow, D. B., Miska, E. A., Langley, E., Reynaud‐Deonauth, S., Kotecha, S., Towers, N., Spohr, G., Kouzarides, T., & Mohun, T. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.18.5085 · Cited by 196
Harrington, A. J., Raissi, A., Rajkovich, K., Berto, S., Kumar, J., Molinaro, G., Raduazzo, J., Guo, Y., Loerwald, K., Konopka, G., et al. (2016) · eLife · doi:10.7554/elife.20059 · Cited by 193
Zhang, Z., Cao, M., Chang, C.-W., Wang, C., Shi, X., Zhan, X., Birnbaum, S. G., Bezprozvanny, I., Huber, K. M., & Wu, J. I. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00534-15 · Cited by 48
Cited by
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Self-citationCutano, V., Di Giorgio, E., Minisini, M., Picco, R., Dalla, E., & Brancolini, C. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12503 · Cited by 44
Self-citationMinisini, M., Di Giorgio, E., Kerschbamer, E., Dalla, E., Faggiani, M., Franforte, E., Meyer-Almes, F.-J., Ragno, R., Antonini, L., Mai, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac081 · Cited by 28
Self-citationHDAC4 in cancer: A multitasking platform to drive not only epigenetic modifications
Cuttini, E., Goi, C., Pellarin, E., Vida, R., & Brancolini, C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1116660 · Cited by 28
Self-citation
Metadata
- Authors
- Di Giorgio, E., Franforte, E., Cefalù, S., Rossi, S., Dei Tos, A. P., Brenca, M., Polano, M., Maestro, R., Paluvai, H., Picco, R., & Brancolini, C.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-04-18
- Volume
- 13
- Issue
- 4
- Pages
- e1006752
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W2607353568
- Cited by
- 56
- References
- 5
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.